Designing Next-Generation Cardiometabolic Outcome Trials for Obesity Medicines US$ 20.88 Min. order: 1 piece ★★★★★ 4.8 (234 reviews) Sold : Login>>
VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes US$ 24.56 Min. order: 1 piece ★★★★★ 4.7 (256 reviews) Sold : Login>>
CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure US$ 28.51 Min. order: 1 piece ★★★★★ 4.4 (43 reviews) Sold : Login>>
Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants - Gabe - 2024 - Diabetes, Obesity and Metabolism US$ 21.97 Min. order: 1 piece ★★★★★ 4.9 (172 reviews) Sold : Login>>
Efficacy and safety of cagrilintide 2.4 mg in adults with overweight/obesity: Data from REDEFINE 1 US$ 21.99 Min. order: 1 piece ★★★★★ 4.5 (231 reviews) Sold : Login>>
Novo Nordisk's latest trial results for its next-generation obesity drug CagriSema disappointed investors by failing to show superior outcomes to existing drugs. ➡️ CagriSema, which includes a nascent form of weight loss US$ 27.53 Min. order: 1 piece ★★★★★ 4.5 (17 reviews) Sold : Login>>